Breaking: PrimeLink Bio Named 2025 Shenzhen Seed Unicorn

The 2025 China (Shenzhen) Unicorn Enterprise Conference, themed “New-Quality Driving, Future Leading,” was held in Shenzhen on July 18, 2025. During the event, the “2025 GEI China Unicorn Report” and the “2025 Shenzhen Unicorn & Gazelle Report” were officially released. PrimeLink Bio secured a spot on the “2025 Shenzhen Seed Unicorn” list, honored for its flexible and modular next-generation ADC platform.

About PrimeLink Bio

Founded in July 2021, PrimeLink Bio is an innovative biopharmaceutical company dedicated to the development of next-generation antibody-drug conjugates (ADCs). Guided by the principle of “tailoring optimal ADC structures for specific targets,” the company has developed a flexible, modular platform that enables novel strategies to overcome the safety liabilities and resistance mechanisms limiting current ADC therapies. Leveraging a highly hydrophilic ADC platform with outstanding compatibility and flexibility, PrimeLink Bio has built a pipeline spanning single-target ADCs and novel modalities such as bispecific ADCs and dual-payload ADCs. Three programs have already reached the PCC stage. The core pipeline’s lead candidate has shown superior efficacy and safety with best-in-class potential in preclinical studies, and its IND application was submitted in Q3 2025. With its differentiated platform and robust pipeline, PrimeLink Bio has consistently attracted top-tier investors and leading pharmaceutical companies, securing 150 million RMB in funding to date. The company will continue to advance its platform and accelerate pipeline development to bring life-changing benefits to cancer patients worldwide.